Abcam, ab300837, Human ANXA2 knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
ANXA2 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma

Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ANXA2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Annexin-2 also known as ANXA2 is a multifunctional protein of approximately 36 kDa. It belongs to the annexin family and is known for its strong calcium-dependent interactions with phospholipid membranes. Commonly expressed in endothelial cells it also appears in various tissues including epithelial cells and certain types of cancer cells. ANXA2 forms a heterotetramer complex with S100A10 also known as p11 which modulates its availability and function. Other names for ANXA2 include its gene designation M298 and its role in complexes often goes by ANXA2R.
Biological function summary
Annexin-2 acts beyond mere cellular structural support. It plays a part in fibrinolysis by acting as a co-receptor for plasminogen and tissue plasminogen activator promoting plasmin generation. The protein is also implicated in membrane trafficking signal transduction and organization of microdomains on cellular surfaces. As part of a complex with S100A10 ANXA2 can bind to cytoskeletal elements facilitating vesicle trafficking and influencing cell shape and motility. This complex assembly hints at ANXA2's importance in maintaining cellular dynamism and interplay with external signals.
Pathways
ANXA2 is integral in the regulation of the plasminogen activation pathway important for fibrinolytic activity. It also participates in the signal transduction pathways influencing cellular responses to stress and growth factors. ANXA2 interacts with various proteins like Src kinase and is involved in processes like the EGFR signaling pathway. This protein often crosstalks with the cytoskeletal network enabling the coupling of membrane dynamics with intracellular signaling cascades.
Annexin-2's dysregulation associates with conditions such as cancer and thrombosis. In cancer overexpression of ANXA2 links with tumor progression invasion and metastasis acting synergistically with proteins like Src to promote oncogenic pathways. In thrombosis ANXA2’s role in fibrinolysis becomes impaired contributing to excessive clot formation. Studies also indicate interactions with plasminogen-related proteins as being central to understanding its pathological roles in these diseases.